SUPPLEMENTARY MATERIAL

Supplementary Note 1. Harmonization of alleles

Before estimating total causal effects, we harmonised our datasets so that the effect estimates of each exposure were coded to express the effect estimate per increasing allele, so that outcome alleles correspond to the same alleles as in the exposure. For genetic variants which are ambiguous (i.e. the forward strand is not clear) the effect allele frequencies of both exposure and outcome are required to employ the harmonization. However, in our analysis allele frequencies were not available in the GWAS of cytokines concentrations and therefore alignment of alleles between exposure and outcome was not feasible in a few cases, resulting in the exclusion of those ambiguous genetic variants due to being "palindromic".

Supplementary Note 2. Sensitivity Analyses

As the validity of MR depends largely on the strength of the genetic instruments, we used the F-statistic to evaluate whether weak instrument bias could have affected our results (1). An F-statistic smaller than 10 indicates that weak instrument bias may be present and causal effect estimates could be biased. Secondly, the estimated total causal effects obtained from IVW method were compared with those obtained from MR-Egger regression and weighted median estimators. Unlike IVW, MR-Egger regression allows for an unconstrained intercept term and provides a robust causal effect estimate, after adjusting for horizontal pleiotropy (2). The weighted median estimator serves as an unbiased causal effect estimate when up to 50% of the instruments are invalid, by estimating the causal effect as the median of the weighted ratio estimates (3). When results from the above methods agree in direction and magnitude, we consider them more likely to be valid. Additionally, the influence of each genetic variant on the outcome was explored by conducting a leave-one out analysis, where genetic variants were systematically removed and causal effects of the remaining SNPs on the outcome were re-estimated (4). In cases where less than three genetic variants were used as instruments, estimation of the MR-Egger and weight median and leave-one out analysis were not feasible. Cochran's Q statistic was used to assess if the causal estimates of all genetic variants within a single MR analysis were comparable.

Substantial heterogeneity is an indication that instruments may not be valid (2). We also applied Steiger to test that the hypothesised causal direction was correct for each SNP (i.e. that that the instruments explain more variation in the exposure than the outcome) (5). Lastly, to further explore the issue of pleiotropic effects of genetic variants, we repeated analyses using only cis-variants (i.e. variants located in the closest proximity to the encoding gene of each cytokine) which are less likely to violate the 'horizontal pleiotropy assumption' than variants who are located more distantly (6). Further information about the procedure followed to extract cis-variants and perform cis-MR can be found in Supplementary Note 3.

Supplementary Note 3. Cis-Mendelian randomization

We defined as *cis* variants all genetic variants located within a 500kb window at either side of the gene that encodes each cytokine. When *cis* variants were available for a cytokine, we further selected independent genome-wide significant variants ($r^2<0.01$ within a 10,000 kb window, $p<5\times10^{-08}$) and corresponding SD-scaled effect sizes and standard errors were extracted from the publicly available datasets (7). After finalizing the list of *cis* variants for each cytokine, we extracted the corresponding log odds and standards errors from the Alzheimer's disease GWAS. Lastly, we performed harmonisation of alleles and estimated the total causal effects of each cytokine concentration on the risk of Alzheimer's disease using the same statistical analysis as in our main analysis (i.e. Wald ratio, IVW, MR-Egger, Weighted Median). More information about the location of each encoding gene and the number of resulting *cis* variants can be found in Table S3

TABLES

Table S1. Characteristics of genetic variants associated with each circulating cytokine concentration.

			trans/cis	Effect/		
Cytokine abbreviation	SNP ID	Chromosome		Ref allele	Beta (SE)	P-value
IL-6*	rs13412535	2	trans	G/A	0.1164 (0.0215)	7.34E-08
	rs72831623	17	trans	A/G	0.1973 (0.0372)	1.08E-07
IL-17	rs1530455	3	trans	T/C	0.1080 (0.0173)	4.87E-10
MCP-1 (CCL2)	rs12075	1	trans	A/G	0.2185 (0.0155)	1.44E-44
	rs2036297	3	trans	A/G	0.1190 (0.0160)	1.09E-13
	rs2228467	3	trans	C/T	0.2637 (0.0291)	9.19E-20
	rs7632755	3	trans	A/G	0.2938 (0.0316)	1.18E-20
MIP1b (CCL4)	rs113010081	3	trans	C/T	0.5954 (0.0236)	3.85E-140
	rs2673050	3	trans	T/G	0.1314 (0.0161)	3.14E-16
	rs4683315	3	trans	G/A	0.1347 (0.0236)	8.97E-09
	rs73074316	3	trans	G/A	0.1436 (0.0216)	2.80E-11
	rs79091774	3	trans	C/A	0.4606 (0.0751)	8.83E-10
	rs10491120	17	trans	A/G	0.3001 (0.0318)	5.15E-21
	rs111942332	17	trans	G/T	0.4727 (0.0573)	1.70E-16
	rs113877493	17	cis	C/T	0.6124 (0.0218)	1.62E-173
	rs117453826	17	trans	G/A	0.5774 (0.0593)	5.07E-22
	rs117620244	17	trans	C/T	0.3528 (0.0495)	1.87E-12
	rs117715247	17	cis	G/A	0.3510 (0.0590)	3.09E-09
	rs17693183	17	trans	G/A	0.5795 (0.0795)	8.93E-13
	rs2190980	17	trans	G/A	0.1067 (0.0167)	1.43E-10
	rs4795162	17	Trans	A/G	0.1261 (0.0158)	1.14E-15
	rs4796072	17	trans	G/T	0.1149 (0.0177)	8.12E-11
	rs60516659	17	cis	A/G	0.2691 (0.0248)	3.64E-27
	rs6505501	17	trans	C/T	0.1556 (0.0191)	3.71E-16
	rs7221878	17	trans	C/T	0.3045 (0.0463)	7.37E-11
	rs76842834	17	trans	C/T	0.4206 (0.0472)	7.33E-19
	rs76960253	17	cis	T/C	0.5233 (0.0585)	5.45E-19
	rs80007108	17	trans	A/C	0.2259 (0.0310)	2.73E-13
	rs9330240	17	trans	C/T	0.4745 (0.0460)	5.84E-25
GROa (CXCL1)	rs12075	1	trans	A/G	0.3751 (0.0237)	1.24E-55
	rs508977	4	cis	G/T	0.3802 (0.0280)	7.56E-42
IFNg*	rs78296352	1	trans	T/G	0.3430 (0.0652)	1.38E-07
IL-4*	rs17713451	7	trans	A/G	0.1274 (0.0253)	4.97E-07
	rs10512267	9	trans	C/T	0.0824 (0.0161)	2.94E-07
IL-10	rs282258	2	trans	T/C	0.0992 (0.0162)	1.00E-09
	rs4349809	6	trans	T/G	0.2853 (0.0165)	5.77E-67
IL-13	rs75438658	6	trans	C/T	0.3430 (0.0625)	4.12E-08
	rs9472168	6	trans	A/G	0.4244 (0.0248)	1.08E-65
IL-7	rs4320361	6	trans	G/T	0.3245 (0.0249)	6.87E-39
IL-2ra	rs12722497	10	cis	A/C	0.6279 (0.0485)	1.57E-38
IL12p70	rs12199215	6	trans	T/C	0.1278 (0.0192)	5.11E-11
	rs4349809	6	trans	T/G	0.3777 (0.0159)	2.56E-124
	rs7754905	6	trans	G/A	0.1029 (0.0190)	4.28E-08
IL-16	rs4253283	4	trans	T/C	0.1460 (0.0262)	1.75E-08
	rs1801020	5	trans	A/G	0.1733 (0.0272)	4.53E-10
	rs4778636	15	cis	G/A	0.7272 (0.0633)	1.11E-30
IL-18	rs385076	2	trans	C/T	0.2432 (0.0248)	1.66E-22

	rs116656892	5	trans	T/C	0.5298 (0.0925)	1.05E-08
	rs17229943	5	trans	C/A	0.3120 (0.0463)	1.62E-11
	rs71478720	11	cis	C/T	0.2669 (0.0276)	3.71E-22
CTACK (CCL27)	rs2070074	9	cis	A/G	0.4467 (0.0374)	1.79E-32
	rs58704839	9	cis	A/G	0.1785 (0.0284)	3.29E-10
	rs55764737	15	trans	T/C	0.5313 (0.0972)	4.62E-08
	rs135564	22	trans	G/A	0.1893 (0.0268)	2.43E-12
Eotaxin	rs12075	1	trans	A/G	0.1671 (0.0156)	1.33E-26
	rs2228467	3	trans	C/T	0.4163 (0.0292)	2.27E-46
	rs3091309	3	trans	A/G	0.1283 (0.0203)	3.63E-10
	rs342511	3	trans	A/G	0.0927 (0.0157)	3.60E-09
	rs2024050	7	cis	A/G	0.1728 (0.0303)	1.10E-08
HGF	rc2749024	1	trans	T/C	0.1405 (0.0224)	1 915 10
nor	155746054 rcE74E697	4	trans		0.1495 (0.0254)	1.01E-1U 2.7EE 14
1010	155/4506/	/	CIS		0.3072 (0.0406)	2.75E-14
	15113831257	4		A/G	0.3592 (0.0644)	2.53E-08
PDGFDD	rs12990266	2	trans	A/G	0.2363 (0.0342)	3.18E-12
	rs13024765	2	trans	C/T	0.1014 (0.0158)	1.14E-10
	rs13412535	2	trans	A/G	0.3352 (0.0214)	2.46E-55
	rs2324229	6	trans	T/C	0.0894 (0.0161)	3.48E-08
	rs28406863	15	trans	G/T	0.2089 (0.0382)	4.78E-08
	rs4965869	15	trans	T/C	0.1840 (0.0181)	5.66E-24
	rs9806745	15	trans	A/C	0.1162 (0.0163)	1.10E-12
SCF	rs1557570	1	trans	T/G	0.1186 (0.0170)	2.74E-12
	rs4841899	9	trans	C/T	0.1004 (0.0178)	1.78E-08
SCGFb	rs4656185	1	trans	A/G	0.2050 (0.0256)	1.16E-15
	rs17876031	5	trans	G/A	0.1514 (0.0255)	2.25E-09
	rs117716477	12	trans	A/C	0.8384 (0.0841)	1.34E-23
	rs73185877	12	trans	A/G	0.5249 (0.0711)	1.18E-13
	rs116924815	19	trans	T/C	0.6079 (0.0738)	1.74E-16
TNF-b	rs116196280	1	trans	T/G	0.7179 (0.1006)	4.98E-13
	rs78296352	1	trans	T/G	1.2215 (0.1366)	4.76E-21
TRAIL	rs3136596	3	cis	A/G	0.1147 (0.0209)	3.65E-08
	rs79287178	3	cis	G/A	0.4317 (0.0421)	9.12E-25
	rs11081739	18	trans	A/G	0.1411 (0.0202)	3.34E-12
	rs193112415	18	trans	C/T	1.0421 (0.0623)	2.15E-62
	rs57396456	18	trans	C/T	0.5626 (0.0518)	1.25E-27
	rs62093514	18	trans	T/C	1.0618 (0.0552)	6.86E-82
	rs62093947	18	trans	C/T	0.7596 (0.046)	3.31E-61
	rs74778900	18	trans	T/C	0.5906 (0.0532)	2.59E-28
	rs77451439	18	trans	G/A	0.4322 (0.0369)	1.21E-31
	rs9952273	18	trans	T/C	0.8640 (0.0499)	3.86E-69
VEGF	rs41282660	6	cis	G/A	0.1613 (0.0263)	1.33E-09
	rs4507572	6	cis	T/C	0.1007 (0.0171)	3.34E-09
	rs67798973	6	cis	A/G	0.1389 (0.0175)	1.29E-15
	rs6920532	6	cis	T/C	0.1803 (0.0267)	8.68E-12
	rs6921438	6	cis	G/A	0.4900 (0.0175)	2.09E-171
	rs74675876	6	cis	C/T	0.2822 (0.0366)	7.62E-15
	rs9381249	6	cis	C/T	0.2482 (0.0397)	3.09E-10
	rs9472183	6	cis	G/A	0.1282 (0.017)	5.19E-14
	rs34881325	9	trans	C/T	0.1082 (0.0189)	1.04E-08
MIG (CXCL9)	rs55876513	4	cis	T/G	0.1660 (0.0255)	8.23E-11
RANTES (CCL5)	rs74472919	13	trans	T/C	0.3313 (0.0605)	3.97E-08
	rs146151667	2	trans	A/G	0.5072 (0.0978)	3.36E-07
	rs35803309	7	trans	A/AT	0.2080 (0.0404)	2.36E-07
		-				

 IL-2*	rs13412535	2	trans	A/G	0.1764 (0.0332)	1.18E-07
IL-5	rs7767396	6	trans	A/G	0.1515 (0.0246)	7.69E-10
IL-8*	rs12075	1	trans	A/G	0.1200 (0.0236)	3.88E-07
IL-9*	rs76963786	12	trans	C/T	0.2865 (0.0557)	4.50E-07
 MCP3*	rs10892381	11	trans	T/C	0.2412 (0.0476)	3.56E-07
 bNGF	rs28637706	19	trans	G/T	0.1589(0.0263)	1.42E-09
 MCSF	rs56367447	8	trans	C/T	0.4967(0.0883)	1.72E-08

* No genetic variants were available on p< 5×10^{-08} threshold. Thus, genetic variants were identified using a more liberal threshold of p< 5×10^{-07} .

Table S2. Characteristics of g	genetic variants associated	with genetic liability to	Alzheimer's disease (Phase1) (8)
	3	8	

SNP ID	Chromosome	Effect/ Ref allele	Beta (SE)	P-value
rs2093760	1	A/G	0.1479 (0.0162)	1.14E-19
rs13004848	2	C/T	0.1202 (0.0205)	4.62E-09
rs6733839	2	T/C	0.1845 (0.0161)	2.60E-30
rs7657553	4	A/G	0.0884 (0. 0159)	2.92E-08
rs9272561	6	G/A	0.1367 (0. 0222)	8.75E-10
rs9381563	6	C/T	0.0922 (0. 0154)	2.16E-09
rs11763230	7	C/T	0.1269 (0. 0185)	7.25E-12
rs1859788	7	G/A	0.0948 (0. 0147)	1.25E-10
rs11787077	8	C/T	0.1399 (0. 0140)	2.09E-23
rs28834970	8	C/T	0.0850 (0. 0149)	1.46E-08
rs10792832	11	G/A	0.1290 (0. 0149)	5.90E-18
rs11218343	11	T/C	0.2577 (0. 0381)	1.51E-11
rs7935829	11	A/G	0.1100 (0. 0134)	3.55E-16
rs12590654	14	G/A	0.0926 (0. 0162)	1.09E-08
rs8093731	18	C/T	0.6136 (0. 1123)	4.66E-08
rs10407439	19	G/A	0.2455 (0. 0180)	1.00E-200
rs11666329	19	A/G	0.2274 (0. 0157)	1.00E-200
rs117310449	19	T/C	1.0823 (0. 0792)	1.00E-200
rs2376866	19	T/C	0.1637 (0. 0208)	4.51E-15
rs3865444	19	C/A	0.0898 (0. 0160)	2.17E-08
rs4147929	19	A/G	0.1219 (0. 0205)	2.93E-09
rs484195	19	G/A	0.3824 (0. 0205)	1.00E-200
rs55923289	19	C/T	0.3358 (0. 0234)	1.00E-200
rs595290	19	C/T	0.1564 (0. 0197)	2.77E-15
rs7412	19	C/T	0.4254 (0. 0359)	2.63E-32
rs899087	19	T/C	0.1952 (0. 0323)	1.65E-09

Cytokine abbreviation	Gene location	No. SNPs	Wald Ratio OR (95% CI)	IVW OR (95% CI)	MR-Egger slope OR (95% CI)	Weighted Median OR (95%CI)
IL2ra	Chr 10: 6,052,652 - 6,104,333	1	0.94 (0.87 to 1.02) p=0.166	N/A	N/A	N/A
VEGF	VEGF A: Chr6: 43,737,921-43,754,224 VEGFB: Chr11: 64,002,010-64,006,259 VEGFC: Chr4: 177,604,689-177,713,895	8	N/A	0.99 (0.93 to 1.05) p=0.796	0.96 (0.86 to 1.06) p=0.460	0.98 (0.93 to 1.04) p= 0.666
IL-16	Chr 15: 81,451,916-81,606,399	1	0.99 (0.93 to 1.06) p=0.930	N/A	N/A	N/A
IL-18	Chr 11: 112,013,974-112,034,840	1	0.97 (0.86 to 1.10) p=0.720	N/A	N/A	N/A
GROa (CXCL1)	Chr 4: 74,735,110-74,737,025	1	1.00 (0.92 to 1.09) p=0.850	N/A	N/A	N/A
MIP1b (CCL4)	Chr17: 34,430,983-34,433,014	6	N/A	1.00 (0.90 to 1.11) p=0.902	1.02 (0.75 to 1.39) p=0.857	0.96 (0.84 to 1.10) p=0.605
TRAIL	Chr 3: 172,223,298-172,241,265	2	N/A	1.23 (0.97 to 1.55) p=0.07	N/A	N/A
HGF	Chr 7: 81,328,326-81,399,754	1	0.99 (0.83 to 1.18) p=0.944	N/A	N/A	N/A
Eotaxin	Chr 7: 75,440,983-75,452,674	1	1.24 (0.92 to 1.66) p=0.142	N/A	N/A	N/A
CTACK (CCL27)	Chr 9: 34,661,877-34,664,045	2	N/A	1.06 (0.91 to 1.24) p=0.412	N/A	N/A
MIG (CXCL9)	Chr 4: 76,922,428-76,928,662	1	1.16 (0.96 to 1.40) p=0.103	N/A	N/A	N/A

Table S3. Causal effects of genetically determined cytokine concentrations on the risk of Alzheimer's disease, as obtained from the cis-MR analysis.



Leave-one out analysis for IL-6

Figure S1. Leave-one out analyses of 1-SD increase in IL-6 on Alzheimer's disease, using IVW. Estimates shown as log odds and 95%CI



Figure S2. Leave-one out analyses of 1-SD increase in MCP1 on Alzheimer's disease, using IVW. Estimates shown as log odds and 95%CI

Leave-one out analysis for MIP1b

SNP ID		Effect Est. (95 % CI)
rs113010081		0.057 (0.00,0.11)
rs2673050	-	0.046 (0.00,0.09)
rs113877493		0.044 (0.00,0.09)
rs10491120		0.043 (-0.01,0.09)
rs4683315		0.043 (0.00,0.09)
rs4795162		0.043 (0.00,0.09)
rs73074316		0.043 (0.00,0.09)
rs17693183	-	0.042 (0.00,0.09)
rs117453826		0.042 (-0.01,0.09)
rs76960253		0.041 (0.00,0.09)
rs80007108		0.041 (-0.01,0.09)
rs117715247		0.041 (-0.01,0.09)
rs117620244		0.04 (-0.01,0.09)
rs111942332		0.04 (-0.01,0.09)
rs9330240		0.04 (-0.01,0.09)
rs4796072		0.039 (-0.01,0.09)
rs76842834		0.039 (-0.01,0.09)
rs7221878		0.039 (-0.01,0.09)
rs79091774		0.035 (-0.01,0.08)
rs6505501		0.034 (-0.01,0.08)
rs60516659		0.034 (-0.01,0.08)
rs2190980		0.032 (-0.02,0.08)
IVW (random effects)	-	0.041 (-0.01,0.09)
-0.5 per 1-SE	0 0.5 Dincrease	

Figure S3. Leave-one out analyses of 1-SD increase in MIP1b on Alzheimer's disease, using IVW. Estimates shown as log odds and 95%CI



Leave-one out analysis for GROa

Figure S4. Leave-one out analyses of 1-SD increase in GROa on Alzheimer's disease, using IVW. Estimates shown as log odds and 95%CI



Leave-one out analysis for IL4

Figure S5. Leave-one out analyses of 1-SD increase in IL-4 on Alzheimer's disease, using IVW. Estimates shown as log odds and 95%CI



SNP ID



Figure S6. Leave-one out analyses of 1-SD increase in IL-10 on Alzheimer's disease, using IVW. Estimates shown as log odds and 95%CI

Leave-one out analysis for IL10





Figure S7. Leave-one out analyses of 1-SD increase in IL-13 on Alzheimer's disease, using IVW. Estimates shown as log odds and 95%CI





Figure S8. Leave-one out analyses of 1-SD increase in IL12p70 on Alzheimer's disease, using IVW. Estimates shown as log odds and 95%CI



Leave-one out analysis for IL16

Figure S9. Leave-one out analyses of 1-SD increase in IL-16 on Alzheimer's disease, using IVW. Estimates shown as log odds and 95%CI



Leave-one out analysis for IL18

Figure S10. Leave-one out analyses of 1-SD increase in IL-18 on Alzheimer's disease, using IVW. Estimates shown as log odds and 95%CI





Figure S11. Leave-one out analyses of 1-SD increase in CTACK on Alzheimer's disease, using IVW. Estimates shown as log odds and 95%CI



Leave-one out analysis for Eotaxin

Figure S12. Leave-one out analyses of 1-SD increase in Eotaxin on Alzheimer's disease, using IVW. Estimates shown as log odds and 95%CI





Figure S13. Leave-one out analyses of 1-SD increase in HGF on Alzheimer's disease, using IVW. Estimates shown as log odds and 95%CI



Leave-one out analysis for PDGFbb

Figure S14. Leave-one out analyses of 1-SD increase in PDGFbb on Alzheimer's disease, using IVW. Estimates shown as log odds and 95%CI





Figure S15. Leave-one out analyses of 1-SD increase in SCF on Alzheimer's disease, using IVW. Estimates shown as log odds and 95%CI



Leave-one out analysis for SCGFb

Figure S16. Leave-one out analyses of 1-SD increase in SCGFb on Alzheimer's disease, using IVW. Estimates shown as log odds and 95%CI





Figure S17. Leave-one out analyses of 1-SD increase in TNFb on Alzheimer's disease, using IVW. Estimates shown as log odds and 95%CI

Leave-one out analysis for TRAIL



Figure S18. Leave-one out analyses of 1-SD increase in TRAIL on Alzheimer's disease, using IVW. Estimates shown as log odds and 95%CI





Figure S19. Leave-one out analyses of 1-SD increase in VEGF on Alzheimer's disease, using IVW. Estimates shown as log odds and 95%CI



Figure S20. Leave-one out analyses of 1-SD increase in IL-1ra on Alzheimer's disease, using IVW. Estimates shown as log odds and 95%CI

Cytokine abbreviation	Method		No.SNPs	OR (95%CI)	pval.	Q - pval.
IL1ra*	IVW IVW		2 2	0.68 (0.40,1.16) 0.90 (0.79,1.04)	0.16 0.15	0.78 0.85
IL6*	IVW IVW	, ∎ (2 2	0.78 (0.58,1.06) 0.96 (0.92,1.00)	0.12 0.03	0.67 0.90
IP10	Wald Ratio	⊧i	1 2	0.89 (0.66,1.22) 1.01 (0.99,1.03)	0.47 0.59	NA 0.66
RANTES (CCL5)	Wald Ratio Wald Ratio	⊨i	1 1	0.94 (0.71,1.24) 1.00 (0.96,1.04)	0.65 0.81	NA NA
IL5	Wald Ratio Wald Ratio	}€ }++1	1 1	0.94 (0.78,1.14) 1.00 (0.97,1.03)	0.54 0.88	NA NA
IL2ra	Wald Ratio Wald Ratio	⊨ - *	1 1	0.95 (0.87,1.02) 1.00 (0.98,1.01)	0.17 0.39	NA NA
IL10	IVW IVW	⊢ 	2 2	0.96 (0.87,1.06) 1.00 (0.97,1.03)	0.40 0.80	0.56 0.04
TNFb	IVW IVW	,, ,	2 2	0.97 (0.82,1.14) 0.99 (0.99,1.00)	0.70 0.18	0.09 0.48
IL12p70	IVW IVW MR-Egger MR-Egger Weighted Median Weighted Median		3 4 3 4 3 4	0.98 (0.92,1.06) 1.00 (0.99,1.01) 0.95 (0.82,1.10) 1.00 (0.98,1.02) 0.98 (0.91,1.06) 1.00 (0.99,1.01)	0.64 0.64 0.48 0.78 0.61 0.75	0.86 0.90 0.90 0.90 NA NA
IFNg*	Wald Ratio Wald Ratio	⊨i ++	1 1	0.97 (0.68,1.39) 0.98 (0.95,1.02)	0.88 0.35	NA NA
MCSF	Wald Ratio Wald Ratio	⊨=(+	1 1	0.97 (0.83,1.14) 1.00 (0.98,1.03)	0.73 0.86	NA NA
IL7	Wald Ratio Wald Ratio	⊨ 	1 1	0.98 (0.89,1.07) 1.00 (0.99,1.02)	0.58 0.74	NA NA
IL13			2	0.98 (0.91,1.05) 0.99 (0.97,1.01)	0.56 0.48	0.29 0.49
		0.50 1.0 1.5 OR per SD increase in cytokine concent	2.0 tration			

Total causal effect of cytokine concentrations on Alzheimer's disease

Figure S21A. Direct comparison of total causal effects of circulating cytokine concentrations on the risk of Alzheimer's disease, as estimated by Wald Ratio, IVW, MR-Egger and Weighted median estimators, using summary data from Phase 1 (■) and Phase 3 (●) of the Alzheimer's GWAS.

Total causal effect of cytokine concentrations on Alzheimer's disease

Cytokine abbreviation	Method		No.SNPs	OR (95%CI)	pval.	Q - pval.
VEGF	IVW IVW MR-Egger MR-Egger Weighted Median Weighted Median		999999	0.99(0.94,1.05) 1.00(0.99,1.01) 0.96(0.87,1.06) 1.00(0.99,1.02) 0.99(0.93,1.05) 1.00(0.99,1.01)	0.77 0.64 0.45 0.78 0.66 0.63	0.37 0.92 0.33 0.87 NA NA
PDGFbb	IVW IVW MR-Egger MR-Egger Weighted Median Weighted Median		7 7 7 7 7 7	0.99(0.89,1.11) 1.01(0.99,1.02) 1.22(1.00,1.48) 1.02(1.00,1.05) 1.04(0.91,1.19) 1.01(1.00,1.02)	0.89 0.35 0.05 0.04 0.55 0.17	0.16 0.29 0.59 0.50 NA NA
bNGF	Wald Ratio Wald Ratio)	1 1	1.00(0.83,1.21) 1.00(0.97,1.02)	0.97	NA
SCGFb	IVW IVW MR-Egger MR-Egger Weighted Median Weighted Median		555555	1.00(0.91,1.11) 1.01(0.99,1.02) 1.16(0.99,1.36) 1.02(1.00,1.04) 1.00(0.90,1.12) 1.01(0.99,1.02)	0.95 0.43 0.07 0.07 1.00 0.43	0.22 0.26 0.73 0.40 NA NA
MCP3*	Wald Ratio Wald Ratio	▶ ──● ──1 ▶●●1	1 1	1.00 (0.87,1.16) 1.00 (0.96,1.05)	0.96 0.91	NA
IL16	IVW IVW MR-Egger MR-Egger Weighted Median Weighted Median		3 3 3 3 3 3 3 3 3 3 3	1.00(0.95,1.06) 0.99(0.98,1.00) 0.99(0.90,1.08) 0.99(0.98,1.01) 1.00(0.94,1.06) 0.99(0.98,1.00)	0.88 0.23 0.82 0.27 0.97 0.24	0.61 0.90 0.37 0.87 NA NA
IL18	IVW IVW MR-Egger MR-Egger Weighted Median Weighted Median		4444444	1.01(0.89,1.14) 1.00(0.98,1.01) 0.44(0.14,1.37) 1.01(0.96,1.07) 1.01(0.92,1.11) 1.00(0.98,1.01)	0.93 0.47 0.15 0.58 0.80 0.56	0.10 0.52 0.21 0.43 NA NA
SCF	IVW IVW	▶ ── →	22	1.02 (0.63,1.64) 1.02 (0.96,1.08)	0.95	0.01
IL17	Wald Ratio Wald Ratio	⊨ 	1 1	1.02 (0.76,1.37) 0.99 (0.95,1.03)	0.90	NA
GROa (CXCL1)	IVW IVW	r + - +	22	1.04 (0.99,1.10) 1.00 (0.99,1.01)	0.15 0.87	0.35 0.35
GROa (CXCL1)	Wald Ratio IVW IVW	0.50 1.0 1.5 OR per SD increase in cytokine concentra	1 2 2.0 tion	0.9 1.0 1.0	9 (0.95,1.03) 4 (0.99,1.10) 0 (0.99,1.01)	9 (0.95,1.03) 0.60 4 (0.99,1.10) 0.15 0 (0.99,1.01) 0.87

Figure S21B. Direct comparison of total causal effects of circulating cytokine concentrations on the risk of Alzheimer's disease, as estimated by Wald Ratio, IVW, MR-Egger and Weighted median estimators, using summary data from Phase 1 (■) and Phase 3 (●) of the Alzheimer's GWAS.

MIP1b (CCL4)						
	IVW	i=1	22	1.04 (0.99,1.09)	0.08	0.82
	IVW .	•	22	1.00(0.99,1.01)	0.95	0.78
	MR-Egger		22	1.01(0.93,1.09)	0.80	0.82
	MR-Egger		22	0.99 (0.98,1.00)	0.03	0.98
	Weighted Median	H -	22	1.01 (0.94,1.07)	0.83	NA
	Weighted Median	•	22	1.00(0.99,1.01)	0.75	NA
IL9*	Wald Ratio	— •—	1	1.04 (0.88, 1.24)	0.62	NA
	Wald Ratio	1-1	1	1.00 (0.96, 1.03)	0.73	NA
TRAIL	IVW	⊢∎⊣	11	1.04 (0.97, 1.12)	0.25	0.38
	IVW	•	11	1.00 (0.99,1.00)	0.36	0.74
	MR-Egger	H	11	1.05 (0.94,1.17)	0.37	0.30
	MR-Egger		11	1.00 (0.99,1.01)	0.77	0.67
	Weighted Median	H	11	1.01(0.91,1.11)	0.91	NA
	Weighted Median	•	11	1.00 (0.99,1.01)	0.82	NA
MCP1 (CCL2)	IVW		4	1.04 (0.94,1.15)	0.50	0.22
	IVW		4	1.00 (0.99, 1.01)	0.94	0.94
	MR-Egger		4 4	1,25(0.91,1.71)	0.18	0.28
	MR-Egger	1+1	4	1.00(0.96.1.05)	0.94	0.83
	Weighted Median	H	4	1.05(0.951.16)	0.34	NA
	Weighted Median	•	4	1.00 (0.99, 1.02)	0.91	NA
IL4"	IVW	· · · · · ·	2	1.07 (0.82,1.39)	0.64	0.63
	IVW	Het	2	1.00 (0.96, 1.04)	0.95	0.42
HGF	IVW		2	1.07 (0.84,1.37)	0.56	0.10
	IVW		2	1.00 (0.97, 1.02)	0.72	0.41
Eotaxin	IVW	H	5	1.08 (0.99, 1.17)	0.10	0.42
	IVW		5	1.00 (0.99, 1.01)	0.88	0.95
	MR-Egger	F	5	1.06 (0.86,1.31)	0.58	0.28
	MR-Egger	I+I	5	0.99 (0.96,1.02)	0.64	0.95
	Weighted Median	⊢− →	5	1.11(1.00,1.24)	0.05	NA
	Weighted Median	•	5	1.00 (0.99, 1.02)	0.88	NA
CTACK (CCL27)	IVW		4	1.09 (1.01, 1.19)	0.03	0.27
	IVW		4	1.00 (0.99,1.02)	0.59	0.16
	MR-Egger	⊢ −−→	4	0.99 (0.83, 1.17)	0.88	0.35
	MR-Egger	1+1	4	1.00 (0.96,1.04)	0.81	0.10
	Weighted Median		4	1.10(1.01,1.20)	0.03	NA
	Weighted Median	•	4	1.00 (0.99,1.01)	0.81	NA
MIG (CXCL9)	Wald Ratio		1	1.17 (0.97,1.41)	0.10	NA
	Wald Ratio	┝━━┥	1	1.05 (0.97,1.13)	0.20	NA
IL8*	Wald Ratio	· · · · · · · · · · · · · · · · · · ·	1	1.21 (0.97,1.51)	0.09	NA
	Wald Ratio	1+1	1	1.01 (0.97, 1.04)	0.66	NA
L2*	Wald Ratio		1	1.21 (0.94, 1.56)	0.14	NA
	Wald Ratio	lei	1	1.03 (1.00,1.06)	0.04	NA

Total causal effect of cytokine concentrations on Alzheimer's disease



Figure S21C. Direct comparison of total causal effects of circulating cytokine concentrations on the risk of Alzheimer's disease, as estimated by Wald Ratio, IVW, MR-Egger and Weighted median estimators, using summary data from Phase 1 (**■**) and Phase 3 (**●**) of the Alzheimer's GWAS.

Cytokine abbreviation	Method	No.SNPs	β (95%CI)	pval.	Q - pva
IL1ra*	IVW IVW MR-Egger MR-Egger Weighted Median Weighted Median	26 29 26 29 26 29	-0.03 (-0.09, 0.03) 0.01 (-0.39, 0.42) -0.07 (-0.18, 0.05) -0.21 (-0.91, 0.48) -0.05 (-0.14, 0.04) 0.00 (-0.58, 0.58)	0.35 0.95 0.28 0.55 0.25 0.99	0.95 0.94 0.94 0.94 NA NA
IP10	IVW IVW MR-Egger MR-Egger Weighted Median Weighted Median	26 29 26 29 26 29 26 29	-0.04 (-0.11, 0.04) -0.24 (-0.67, 0.20) -0.12 (-0.26, 0.02) -0.17 (-0.92, 0.59) -0.11 (-0.20, -0.02) -0.02 (-0.62, 0.57)	0.32 0.29 0.10 0.67 0.02 0.94	0.06 0.23 0.08 0.19 NA NA
RANTES (CCL5)	IVW IVW MR-Egger MR-Egger Weighted Median Weighted Median	26 29 26 29 26 29	0.01 (-0.06, 0.07) -0.09 (-0.50, 0.33) -0.06 (-0.18, 0.06) -0.86 (-1.57, -0.15) -0.01 (-0.09, 0.08) -0.35 (-0.96, 0.26)	0.85 0.69 0.33 0.02 0.88 0.26	0.98 0.63 0.99 0.90 NA NA
IL5	IVW IVW MR-Egger MR-Egger Weighted Median Weighted Median	26 29 26 29 26 29 26 29	0.00 (-0.06, 0.06) 0.10 (-0.32, 0.53) 0.00 (-0.12, 0.12) 0.02 (-0.72, 0.75) 0.00 (-0.09, 0.09) 0.01 (-0.61, 0.63)	0.99 0.63 1.00 0.97 0.96 0.98	0.67 0.52 0.61 0.47 NA NA
IL2ra	IVW IVW MR-Egger MR-Egger Weighted Median Weighted Median	26 29 26 29 26 29	-0.05 (-0.11, 0.02) 0.06 (-0.41, 0.54) -0.12 (-0.25, 0.01) -0.59 (-1.35, 0.17) -0.04 (-0.14, 0.05) -0.24 (-0.87, 0.39)	0.19 0.79 0.08 0.13 0.37 0.45	0.15 0.08 0.17 0.18 NA NA
IL10	IVW IVW MR-Egger MR-Egger Weighted Median Weighted Median	26 29 26 29 26 29 26 29	-0.01 (-0.06, 0.05) 0.00 (-0.28, 0.28) -0.02 (-0.13, 0.10) 0.15 (-0.33, 0.63) 0.01 (-0.06, 0.08) -0.15 (-0.55, 0.25)	0.76 0.99 0.76 0.53 0.82 0.47	0.01 0.42 0.01 0.40 NA NA
IL12p70	IVW IVW MR-Egger MR-Egger Weighted Median Weighted Median	26 29 26 29 26 29 26 29	0.00 (-0.05, 0.05) 0.13 (-0.14, 0.39) 0.01 (-0.09, 0.11) 0.30 (-0.15, 0.75) 0.04 (-0.02, 0.11) 0.06 (-0.32, 0.45)	0.93 0.36 0.85 0.19 0.19 0.74	0.04 0.63 0.03 0.63 NA NA

per log OR increase in Alzheimer's disease genetic liability

Figure S22A. Direct comparison of total causal effect genetic liability to Alzheimer's disease on circulating cytokine concentrations, as estimated by Wald Ratio, IVW, MR-Egger and Weighted median estimators, using summary data from Phase 1 (\blacksquare) and Phase 3 (\bullet) of the Alzheimer's GWAS.

Cytokine abbreviation	Method		No.SNPs	β (95%CI)	pval.	Q - pval.
IFNg*	IVW IVW MR-Egger MR-Egger Weighted Median Weighted Median		26 29 26 29 26 29	-0.01 (-0.05, 0.03) 0.14 (-0.14, 0.42) -0.03 (-0.12, 0.05) 0.22 (-0.24, 0.69) -0.01 (-0.08, 0.05) 0.24 (-0.18, 0.67)	0.59 0.32 0.46 0.35 0.71 0.26	0.40 0.59 0.37 0.55 NA NA
MCSF	IVW IVW MR-Egger MR-Egger Weighted Median Weighted Median		26 29 26 29 26 29	-0.06 (-0.14, 0.01) 0.04 (-0.50, 0.57) 0.00 (-0.15, 0.14) 0.26 (-0.67, 1.19) -0.03 (-0.14, 0.07) 0.22 (-0.48, 0.92)	0.10 0.89 0.96 0.58 0.51 0.54	0.62 0.22 0.61 0.20 NA NA
IL7	IVW IVW MR-Egger MR-Egger Weighted Median Weighted Median		26 29 26 29 26 29	0.01 (-0.06, 0.07) 0.28 (-0.15, 0.71) 0.05 (-0.09, 0.18) 0.33 (-0.42, 1.09) 0.04 (-0.05, 0.14) 0.28 (-0.33, 0.90)	0.84 0.20 0.49 0.38 0.36 0.36	0.26 0.41 0.24 0.36 NA NA
IL13	IVW IVW MR-Egger MR-Egger Weighted Median Weighted Median		26 29 26 29 26 29	-0.01 (-0.07, 0.05) -0.04 (-0.45, 0.37) 0.01 (-0.11, 0.13) 0.00 (-0.70, 0.70) 0.03 (-0.07, 0.12) -0.06 (-0.65, 0.54)	0.78 0.85 0.91 1.00 0.57 0.85	0.65 0.96 0.60 0.94 NA NA
VEGF	IVW IVW MR-Egger MR-Egger Weighted Median Weighted Median		26 29 26 29 26 29	-0.02 (-0.08, 0.05) -0.07 (-0.39, 0.25) 0.02 (-0.10, 0.15) 0.47 (-0.02, 0.96) 0.03 (-0.04, 0.10) 0.13 (-0.32, 0.57)	0.61 0.66 0.71 0.06 0.41 0.58	0.00 0.20 0.00 0.47 NA NA
PDGFbb	IVW IVW MR-Egger MR-Egger Weighted Median Weighted Median		26 29 26 29 26 29	-0.01 (-0.05, 0.04) -0.02 (-0.29, 0.25) -0.01 (-0.09, 0.07) -0.02 (-0.47, 0.43) 0.03 (-0.03, 0.08) -0.11 (-0.49, 0.27)	0.80 0.88 0.83 0.94 0.37 0.56	0.43 0.75 0.38 0.71 NA NA
bNGF	IVW IVW MR-Egger MR-Egger Weighted Median		26 29 26 29 26 29	-0.01 (-0.08, 0.06) 0.15 (-0.30, 0.60) 0.00 (-0.14, 0.14) 0.02 (-0.76, 0.81) -0.03 (-0.13, 0.06) -0.18 (-0.82, 0.45)	0.72 0.52 1.00 0.95 0.50 0.57	0.15 0.20 0.12 0.17 NA NA
	-1.5	0	1.5			
	per log OF	R increase in Alzheimer's disease gene	tic liability			

Figure S22B. Direct comparison of total causal effect genetic liability to Alzheimer's disease on circulating cytokine concentrations, as estimated by Wald Ratio, IVW, MR-Egger and Weighted median estimators, using summary data from Phase 1 (\blacksquare) and Phase 3 (\bullet) of the Alzheimer's GWAS.

Cytokine abbreviation	Method		No.SNPs	β (95%CI)	pval.	Q - pval
SCGFb	IVW IVW MR-Egger MR-Egger Weighted Median Weighted Median		26 29 26 29 26 29	-0.06 (-0.12, 0.01) -0.74 (-1.16,-0.33) -0.12 (-0.24, 0.00) -1.11 (-1.82,-0.41) -0.05 (-0.15, 0.04) -1.05 (-1.66,-0.43)	0.08 0.00 0.06 0.00 0.24 0.00	0.36 0.36 0.38 0.39 NA NA
MCP3*	IVW IVW MR-Egger MR-Egger Weighted Median Weighted Median		23 26 23 26 23 26 23 26	-0.04 (-0.16, 0.08) -0.38 (-1.23, 0.48) 0.16 (-0.09, 0.42) 0.30 (-1.71, 2.31) -0.05 (-0.23, 0.12) -0.07 (-1.31, 1.17)	0.51 0.39 0.21 0.77 0.54 0.91	0.56 0.52 0.69 0.49 NA NA
IL16	IVW IVW MR-Egger MR-Egger Weighted Median Weighted Median		26 29 26 29 26 29	0.03 (-0.04, 0.10) -0.18 (-0.64, 0.29) 0.00 (-0.14, 0.14) -0.28 (-1.10, 0.53) 0.04 (-0.05, 0.13) -0.17 (-0.76, 0.42)	0.46 0.98 0.50 0.38 0.57	0.14 0.14 0.12 0.12 NA NA
IL18	IVW IVW MR-Egger MR-Egger Weighted Median Weighted Median		26 29 26 29 26 29	-0.05 (-0.12, 0.02) -0.39 (-0.82, 0.04) -0.05 (-0.19, 0.08) -0.17 (-0.91, 0.57) -0.07 (-0.17, 0.02) -0.58 (-1.20, 0.04)	0.14 0.08 0.46 0.65 0.14 0.07	0.20 0.27 0.16 0.25 NA NA
SCF	IVW IVW MR-Egger MR-Egger Weighted Median Weighted Median		26 29 26 29 26 29	-0.01 (-0.06, 0.04) 0.16 (-0.15, 0.48) -0.01 (-0.11, 0.09) 0.09 (-0.45, 0.62) 0.03 (-0.03, 0.09) 0.01 (-0.39, 0.40)	0.65 0.30 0.85 0.76 0.37 0.98	0.08 0.09 0.06 0.07 NA NA
IL17	IVW IVW MR-Egger MR-Egger Weighted Median Weighted Median		26 29 26 29 26 29	-0.01 (-0.05, 0.03) -0.08 (-0.19, 0.36) -0.01 (-0.09, 0.08) 0.28 (-0.19, 0.75) -0.01 (-0.07, 0.06) 0.13 (-0.30, 0.55)	0.66 0.56 0.90 0.24 0.85 0.56	0.43 0.73 0.37 0.74 NA NA
GROa (CXCL1)	IVW IVW MR-Egger MR-Egger Weighted Median Weighted Median		26 29 26 29 26 29	-0.02 (-0.10, 0.06) -0.11 (-0.60, 0.38) -0.04 (-0.20, 0.13) -0.07 (-0.92, 0.78) -0.06 (-0.16, 0.04) -0.35 (-0.98, 0.28)	0.67 0.65 0.67 0.87 0.22 0.28	0.02 0.07 0.01 0.05 NA NA
		-1.5 0	1.5			

per log OR increase in Alzheimer's disease genetic liability

Figure S22C. Direct comparison of total causal effect genetic liability to Alzheimer's disease on circulating cytokine concentrations, as estimated by Wald Ratio, IVW, MR-Egger and Weighted median estimators, using summary data from Phase 1 (\blacksquare) and Phase 3 (\bullet) of the Alzheimer's GWAS.

Cytokine abbreviation	Method	No.SNPs	β (95%CI)	pval.	Q - pval
MIP1b (CCL4)	IVW IVW MR-Egger MR-Egger Weighted Median	26 29 26 29 29	-0.01 (-0.06, 0.04) -0.04 (-0.31, 0.24) 0.00 (-0.09, 0.10) 0.19 (-0.27, 0.65) -0.02 (-0.43, 0.39)	0.77 0.79 0.94 0.42 0.92	0.06 0.38 0.05 0.40 NA
IL9*	IVW IVW MR-Egger MR-Egger Weighted Median Weighted Median	26 29 26 29 26 29	-0.02 (-0.08, 0.05) -0.07 (-0.47, 0.33) -0.05 (-0.17, 0.07) -0.37 (-1.06, 0.32) -0.02 (-0.11, 0.06) -0.39 (-0.98, 0.20)	0.63 0.74 0.44 0.29 0.60 0.20	0.90 0.53 0.88 0.54 NA NA
TRAIL	IVW IVW MR-Egger MR-Egger Weighted Median Weighted Median	26 29 26 29 26 29 26 29	-0.01 (-0.05, 0.03) 0.21 (-0.10, 0.51) 0.02 (-0.06, 0.10) 0.26 (-0.27, 0.79) 0.00 (-0.05, 0.06) 0.14 (-0.28, 0.55)	0.75 0.18 0.67 0.33 0.90 0.53	0.89 0.12 0.87 0.10 NA NA
MCP1 (CCL2)	IVW IVW MR-Egger MR-Egger Weighted Median Weighted Median	26 29 26 29 26 29	-0.04 (-0.09, 0.02) -0.14 (-0.51, 0.22) 0.00 (-0.10, 0.11) 0.23 (-0.38, 0.84) -0.01 (-0.07, 0.06) -0.26 (-0.69, 0.16)	0.20 0.44 0.96 0.46 0.81 0.22	0.01 0.00 0.01 0.01 NA NA
IL4*	IVW IVW MR-Egger MR-Egger Weighted Median Weighted Median	26 29 26 29 26 29 26 29	-0.02 (-0.07, 0.03) 0.01 (-0.26, 0.28) -0.01 (-0.10, 0.09) 0.05 (-0.41, 0.52) -0.01 (-0.08, 0.05) -0.07 (-0.47, 0.33)	0.40 0.95 0.85 0.82 0.66 0.73	0.10 0.44 0.08 0.39 NA NA
HGF	IVW IVW MR-Egger MR-Egger Weighted Median Weighted Median	26 29 26 29 26 29 26 29	-0.01 (-0.05, 0.03) 0.09 (-0.18, 0.35) 0.05 (-0.03, 0.13) 0.21 (-0.24, 0.66) 0.00 (-0.06, 0.06) -0.01 (-0.41, 0.39)	0.78 0.51 0.21 0.36 0.90 0.95	0.48 0.54 0.58 0.51 NA NA
Eotaxin	IVW IVW MR-Egger MR-Egger Weighted Median Weighted Median	26 29 26 29 26 29 26 29	$\begin{array}{c} 0.01 \left(\begin{array}{c} -0.03 \\ 0.06 \end{array} \right) \\ 0.12 \left(\begin{array}{c} -0.14 \\ 0.39 \end{array} \right) \\ 0.09 \left(\begin{array}{c} 0.00 \\ 0.07 \\ 0.39 \end{array} \right) \\ 0.39 \left(\begin{array}{c} -0.07 \\ 0.084 \end{array} \right) \\ 0.04 \left(\begin{array}{c} -0.02 \\ 0.10 \end{array} \right) \\ 0.02 \left(\begin{array}{c} -0.38 \\ 0.42 \end{array} \right) \end{array}$	0.51 0.37 0.04 0.09 0.24 0.92	0.24 0.49 0.38 0.55 NA NA

per log OR increase in Alzheimer's disease genetic liability

Figure S22D. Direct comparison of total causal effect genetic liability to Alzheimer's disease on circulating cytokine concentrations, as estimated by Wald Ratio, IVW, MR-Egger and Weighted median estimators, using summary data from Phase 1 (**■**) and Phase 3 (**●**) of the Alzheimer's GWAS.

Cytokine abbreviation	Method		No.SNPs	β (95%CI)	pval.	Q - pval.
CTACK (CCL27)	IVW	=	26	-0.04 (-0.11, 0.02)	0.20	0.19
	IVW	⊢ •–⊣	29	-0.24 (-0.65, 0.16)	0.24	0.61
	MR-Egger	H	26	0.00 (-0.14, 0.13)	0.95	0.17
	MR-Egger	⊢ (29	0.04 (-0.65, 0.74)	0.90	0.61
	Weighted Median	H	26	-0.03 (-0.13, 0.06)	0.47	NA
	Weighted Median	• •	29	-0.20 (-0.79, 0.38)	0.50	NA
MIG (CXCL9)	IVW	=	26	-0.03 (-0.09, 0.03)	0.31	0.58
	IVW	⊢ •−1	29	-0.12 (-0.53, 0.28)	0.55	0.43
	MR-Egger	HEH	26	-0.04 (-0.16, 0.07)	0.46	0.53
	MR-Egger	⊢	29	-0.33 (-1.02, 0.37)	0.36	0.40
	Weighted Median	HEH	26	-0.07 (-0.16, 0.02)	0.10	NA
	Weighted Median	⊢ −−−1	29	-0.18 (-0.79, 0.43)	0.57	NA
IL8*	IVW		26	-0.05 (-0.12, 0.02)	0.14	0.20
	IVW	⊢ •−−1	29	0.18 (-0.24, 0.59)	0.40	0.85
	MR-Egger	⊦∎⊣	26	-0.05 (-0.19, 0.08)	0.46	0.16
	MR-Egger	⊢ •	29	0.24 (-0.46, 0.95)	0.50	0.82
	Weighted Median	H	26	-0.07 (-0.17, 0.02)	0.14	NA
	Weighted Median	⊢	29	0.02 (-0.58, 0.62)	0.95	NA
IL2*	IVW	-	26	0.04 (-0.02, 0.10)	0.20	0.90
	IVW	⊢ 1	29	0.33 (-0.08, 0.75)	0.11	0.96
	MR-Egger	H e -I	26	0.04 (-0.08, 0.16)	0.54	0.87
	MR-Egger	⊢ → 1	29	0.16 (-0.56, 0.88)	0.66	0.96
	Weighted Median	ŀ■ł	26	0.05 (-0.04, 0.14)	0.27	NA
	Weighted Median	⊢ −●−−−1	29	022(-037.081)	0.46	NA

per log OR increase in Alzheimer's disease genetic liability

Figure S22E. Direct comparison of total causal effect genetic liability to Alzheimer's disease on circulating cytokine concentrations, as estimated by Wald Ratio, IVW, MR-Egger and Weighted median estimators, using summary data from Phase 1 (**■**) and Phase 3 (**●**) of the Alzheimer's GWAS.

REFERENCES

1. Burgess S, Thompson SG, Collaboration CCG. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol. 2011;40(3):755-64.

2. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512-25.

3. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet Epidemiol. 2016;40(4):304-14.

4. Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017;32(5):377-89.

5. Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS Genet. 2017;13(11):e1007081.

6. Schmidt AF, Finan C, Gordillo-Marañón M, Asselbergs FW, Freitag DF, Patel RS, et al. Genetic drug target validation using Mendelian randomization. 2019:781039.

7. Ahola-Olli AV, Wurtz P, Havulinna AS, Aalto K, Pitkanen N, Lehtimaki T, et al. Genome-wide Association Study Identifies 27 Loci Influencing Concentrations of Circulating Cytokines and Growth Factors. Am J Hum Genet. 2017;100(1):40-50.

8. Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S, et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. Nat Genet. 2019;51(3):404-13.